Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17833165 | 0.87 | LMNA (0.37) | LMNAL3MBTL1KDM4ETDP1PAOX | |
| SCHEMBL19707949 | 0.83 | LMNA (0.40) | LMNAL3MBTL1KDM4ETDP1PDE4A | |
| SCHEMBL17833039 | 0.81 | KDM4E (0.50) | LMNAL3MBTL1KDM4ETDP1MAPT | |
| SCHEMBL13296277 | 0.77 | LMNA (0.54) | LMNAL3MBTL1KDM4ETDP1ALDH1A1 | |
| SCHEMBL2991748 | 0.77 | LMNA (0.54) | LMNAL3MBTL1KDM4ETDP1ALDH1A1 | |
| SCHEMBL14147721 | 0.77 | LMNA (0.54) | LMNAL3MBTL1KDM4ETDP1ALDH1A1 | |
| SCHEMBL17108622 | 0.77 | LMNA (0.54) | LMNAL3MBTL1KDM4ETDP1ALDH1A1 | |
| SCHEMBL3685829 | 0.77 | KDM4E (0.56) | LMNAL3MBTL1KDM4ETDP1PDE4A | |
| SCHEMBL3371743 | 0.77 | KDM4E (0.56) | LMNAL3MBTL1KDM4ETDP1PDE4A | |
| SCHEMBL3371251 | 0.77 | KDM4E (0.56) | LMNAL3MBTL1KDM4ETDP1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4104865-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3468996-B1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2017214335-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214282-A1 | ANTI-EGFR ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| WO-2017214462-A2 | ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-12-14 | — | — | US | disclosed |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | ABBVIE INC. (US) | 2016-11-24 | — | — | US | disclosed |
| WO-2016094509-A1 | BCL XL INHIBITORY COMPOUNDS HAVING LOW CELL PERMEABILITY AND ANTIBODY DRUG CONJUGATES INCLUDING THE SAME | ABBVIE INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355769-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | LMNA 4613/4885L3MBTL1 1940/4885KDM4E 424/4885 |
| US-20160339117-A1 | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same | BCL2, BAX, BCL9 | LMNA 1814/4885L3MBTL1 1458/4885KDM4E 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.